UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 8, 2016
ALLERGAN PLC
(Exact Name of Registrant as Specified in Charter)
Ireland | 001-36867 | 98-1114402 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
Clonshaugh Business and Technology Park
Coolock, Dublin, D17 E400, Ireland
(Address of Principal Executive Offices)
(862) 261-7000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Item 2.02 | Results of Operations and Financial Condition. |
The information furnished in this Item 2.02 and in Exhibit 99.1 shall not be deemed to be filed for purposes of the Securities Exchange Act of 1934 as amended, nor shall it be deemed to be incorporated by reference in any filing of Allergan plc, except as shall be expressly set forth by specific reference in such filing.
As described in Item 7.01 below, on August 8, 2016, Allergan plc (the Company) announced a realignment of its businesses to streamline operations and provided recast segment contribution for the three months ended June 30, 2016, March 31, 2016, December 31, 2015, September 30, 2015, June 30, 2015 and March 31, 2015. A copy of the recast segment information is attached to this report as Exhibit 99.1 and incorporated herein by reference.
The information in Item 7.01 below is incorporated herein by reference.
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On August 2, 2016, the Compensation Committee of the Board of Directors (the Compensation Committee) of Allergan plc (the Company) approved the amendment of the Transformation Incentive Awards (the TIP Award) granted to certain executives under the Amended and Restated 2013 Incentive Award Plan of Allergan plc (the Allergan Plan) to eliminate the non-GAAP earnings per share goal (the EPS Goal). As a result of the amendment, amounts under the TIP Award will be earned solely based on achievement of the pre-established total shareholder return (relative to the pre-established peer group) goal approved by the Committee in connection with the grant of the TIP Award (the Relative TSR Goal) during the period from the March 17, 2015 through December 31, 2018 (the TSR Performance Period), and will remain payable, if earned, in two equal installments on December 31, 2018 and December 31, 2019, subject to the holders continued employment.
The TIP Award was granted to members of the Companys senior management team, including the named executive officers, in connection with the Companys merger with Allergan, Inc. (the Allergan Acquisition), which closed on March 17, 2015, to incentivize our executives to deliver superior performance during the critical years immediately following the Allergan Acquisition. At the time the TIP Award was granted, payment of the TIP Award was based on achievement of two performance measures that were directly related to managements execution of the Companys business plan during the post-closing transition period. These performance measures were the EPS Goal and Relative TSR Goal. Subsequently, the Company entered into an agreement to divest its generics business (Allergan Generics) to Teva Pharmaceutical Industries Ltd. (Teva). Upon closing on August 2, 2016, the Company received $33.4 billion in cash and 100.3 million shares of Teva stock valued at $5.4 billion based on the opening price of Teva shares on the date of closing, and completed the Companys most crucial step in its evolution into a focused Branded Growth Pharma leader. However, the divestiture of the generics business will result in meaningful reduction to the Companys going forward revenue and earnings. Given this meaningful change, the Compensation Committee determined that the EPS Goal was no longer a suitable metric to measure the performance of our management team, and would not serve to incentivize our executives continued integration efforts following the Allergan Acquisition.
After discussion and careful deliberation, the Compensation Committee determined to eliminate the EPS Goal, making the Relative TSR Goal the sole performance measure in the TIP Award. In making this determination, the Compensation Committee considered, among other things, that the Relative TSR Goal would currently result in no payout of the TIP Award and will only reward our management team for sustained over-performance and execution of critical operational objectives during the 45-month TSR Performance Period, providing immediate shareholder alignment. The Relative TSR Goal and vesting schedule remains unchanged as set forth below:
TIP Award Performance Period: March 17, 2015 December 31, 2018 | ||||
Relative TSR Percentile Rank | TSR Vesting Percentage1 | |||
<50th Percentile | 0 | |||
Threshold Level |
50th Percentile | 75% | ||
Target Level |
60th Percentile | 100% | ||
Maximum Level |
90th Percentile | 200% | ||
Current Payout2 |
38th Percentile | 0% |
1 Vesting between levels occurs via linear interpolation
2 As of date of approved amendment to the Transformation Incentive Awards (August 2, 2016)
Additionally, the Compensation Committee considered that the Relative TSR Goal reflects long-term performance, due to the length of the TSR Performance Period (45 months), is a durable goal as we continue to grow in size and complexity, will be easy to communicate to our management team and promotes executive retention due to the payment schedule.
The foregoing summary of the amendment to the Transformation Incentive Award does not purport to be complete and is subject to and qualified in its entirety by reference to the terms and conditions of the Amended and Restated Transformation Incentive Award Agreement, which is attached hereto as Exhibit 10.1 and is incorporated by reference herein.
Item 7.01. | Regulation FD Disclosure. |
In the second quarter of 2016, the Company announced a realignment of its businesses to streamline operations. Prior to the realignment, the Company operated and managed its business as four distinct operating segments: US Brands, US Medical Aesthetics, International and Anda Distribution. Under the new organizational structure being reported, and the decision to hold for sale our Anda Distribution business, the Company organized its businesses into the following segments: US Specialized Therapeutics, US General Medicine and International. In addition, certain revenues and shared costs, and the results of corporate initiatives, are managed outside of the three segments. Prior period results have been recast to align to the current segment presentation.
The operating segments are organized as follows:
| The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the US, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. |
| The US General Medicine segment includes sales and expenses relating to branded products within the US that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Womens Health, Anti-Infectives and Established Brands. |
| The International segment includes sales and expenses relating to products sold outside the US. |
The Company evaluates segment performance based on segment contribution. Segment contribution for our segments represents net revenues less cost of sales (defined below), selling and marketing expenses, and select general and administrative expenses. Included in segment revenues are products sales that are sold through the Anda Distribution business once the Anda Distribution business has sold the product to a third party customer. These sales are included in segment results and are reclassified into revenues from discontinued operations through a reduction of Corporate revenues which eliminates the sales made by our Anda Distribution business from results of continuing operations. Cost of sales for these products in discontinued operations is equal to our average third party cost of sales for third party brand products distributed by Anda Distribution. The Company does not evaluate the following items at the segment level:
| Revenues and operating expenses within cost of sales, selling and marketing expenses, and general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs. |
| General and administrative expenses that result from shared infrastructure, including certain expenses located within the United States. |
| Total assets including capital expenditures. |
| Other select revenues and operating expenses including research and development expenses (R&D), amortization, in-process research and development (IPR&D) impairments and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments. |
The Company defines segment net revenues as product sales and other revenue derived from branded products or licensing agreements.
Cost of sales within segment contribution includes standard production and packaging costs for the products the Company manufactures, third party acquisition costs for products manufactured by others, profit-sharing or royalty payments for products sold pursuant to licensing agreements and finished goods inventory reserve charges. Cost of sales included within segment contribution does not include non-standard production costs, such as non-finished goods inventory obsolescence charges, manufacturing variances and excess capacity utilization charges, where applicable. Cost of sales does not include amortization or impairment costs for acquired product rights or other acquired intangibles.
Selling and marketing expenses consist mainly of personnel-related costs, product promotion costs, distribution costs, professional service costs, insurance, depreciation and travel costs.
General and administrative expenses consist mainly of personnel-related costs, facilities costs, transaction costs, insurance, depreciation, litigation and settlement costs and professional services costs which are general in nature and attributable to the segment.
Exhibit 99.1 to this Form 8-K provides recast segment contribution as defined above for the three months ended June 30, 2016, March 31, 2016, December 31, 2015, September 30, 2015, June 30, 2015 and March 31, 2015.
The recasting of previously issued financial information does not represent a restatement of previously issued financial statements and does not affect the Companys reported net (loss) / income, earnings per share, total assets, or stockholders equity for any of the previously reported periods. The information contained in this Form 8-K is being furnished pursuant to Regulation FD in order to provide the financial community with historical financial data that is presented on a basis consistent with the Companys new reporting structure. Beginning with the quarter ended June 30, 2016, the Companys financial statements reflect the new reporting structure with prior periods adjusted accordingly.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 | Financial Statements and Exhibits. |
d. | Exhibits: |
10.1 | A&R Other Cash-based Award Agreement | |
99.1 | Segment contribution of Allergan plc for the three months ended June 30, 2016, March 31, 2016, December 31, 2015, September 30, 2015, June 30, 2015 and March 31, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 8, 2016 | Allergan plc | |||||
By: | /s/ Maria Teresa Hilado | |||||
Name: | Maria Teresa Hilado | |||||
Title: | Chief Financial Officer |
EXHIBIT INDEX
Exhibit No. |
Description | |
10.1 | A&R Other Cash-based Award Agreement | |
99.1 | Segment contribution of Allergan plc for the three months ended June 30, 2016, March 31, 2016, December 31, 2015, September 30, 2015, June 30, 2015 and March 31, 2015. |
Exhibit 10.1
EXHIBIT 1-A
A&R OTHER CASH-BASED AWARD AGREEMENT
THIS AMENDED & RESTATED OTHER CASH-BASED AWARD AGREEMENT (this Award Agreement), dated as of [●], is made by and between Allergan plc, a public limited company organized under the laws of Ireland (the Company), as successor to Actavis, Inc., and the Employee whose name and signature appears on the Notice of Grant and Signature Page hereof (Holder).
WHEREAS, the Company granted Holder an Other Cash-Based Award (the Award), pursuant to the terms and conditions and restrictions of the Notice of Grant and Signature Page, this Other Cash-Based Award Agreement (including, in the case of Foreign Holders, the Foreign Country Appendix) and The Amended and Restated 2013 Incentive Award Plan of Allergan plc, as amended from time to time (the terms of which are hereby incorporated by reference and made a part of this Award Agreement, the Plan); and
WHEREAS, in connection with the divestiture of the Companys generics business and consistent with the adjustment provisions provided in this Award Agreement and the Adjustments and Defined Terms Appendix to this Award Agreement, the Committee has determined that it would be to the advantage and best interest of the Company and its shareholders to amend the Award to modify the performance criteria underlying the Award in order for the Award to adequately serve as an inducement for Holder to enter into or remain in the service of the Company or its Subsidiaries and as an incentive for increased efforts during such service and to restate the terms and conditions of the Award.
NOW, THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto do hereby agree as follows:
ARTICLE I
GRANT OF AWARD
Section 1.1 Grant of Award. In consideration of the recitals, Holders agreement to remain in the employ of the Company or a Subsidiary, and for other good and valuable consideration, the Company granted to Holder an Award on the Date of Grant as specified in the Notice of Grant and Signature Page upon the terms and conditions set forth in this Award Agreement (including, in the case of Foreign Holders, the Foreign Country Appendix).
Section 1.2 - Consideration to the Company. As partial consideration for the grant of the Other Award by the Company, Holder agreed to render faithful and efficient services to the Company or a Subsidiary. Nothing in this Award Agreement or in the Plan shall confer upon Holder any right to continue in the employ or services of the Company or any Subsidiary, or as a director of the Company, or shall interfere with or restrict in any way the rights of the Company and any Subsidiary, which are hereby expressly reserved, to discharge Holder at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written employment or other agreement between Holder and the Company and any Subsidiary.
Section 1.3 - Adjustments. The Compensation Committee may adjust the Award in accordance with the provisions of Section 12.3 of the Plan. In addition, the Compensation Committee shall equitably adjust or modify the performance goals set forth herein as set forth on the Adjustments and Defined Terms Appendix to this Award Agreement.
ARTICLE II
VESTING AND PAYMENT OF AWARD
Section 2.1 Vesting.
(a) Upon Completion of the TSR Performance Period. Subject to Section 2.1(b) below, as soon as reasonably practicable following the completion of the TSR Performance Period, the Compensation Committee shall determine the Relative TSR Percentile Rank, the TSR Vesting Percentage and the Total Vested Award in each case, as of the last day of the TSR Performance Period (the First Vesting Date) and fifty percent (50%) of the Total Vested Award shall thereupon become vested as of such First Vesting Date. The remaining fifty percent (50%) of the Total Vested Award shall become vested as of December 31, 2019 (the Second Vesting Date and together with the First Vesting Date, the Vesting Dates), subject to Holders continued employment with the Company or any Subsidiary through such date.
(b) Upon Change in Control. Notwithstanding anything in Section 2.1(a) to the contrary, in the event that a Change in Control occurs prior to the completion of the TSR Performance Period, the Compensation Committee shall determine for such incomplete TSR Performance Period the Relative TSR Percentile Rank, the TSR Vesting Percentage and the Total Vested Award, in each case, as of the date on which such Change in Control occurs (based on actual performance through such date and assuming that the date of such Change in Control is the last day of the incomplete TSR Performance Period); provided, however, that if Holders Total Vested Award, as determined in accordance with the foregoing, is less than Holders Total Target Award, as applicable, then Holder shall instead be eligible to receive Holders Total Target Award. Fifty percent (50%) of the Total Vested Award or Total Target Award, as applicable (and as determined pursuant to this Section 2.1(b)), shall become vested upon the First Vesting Date, and the remaining fifty percent (50%) of the Total Vested Award or Total Target Award, as applicable (and as determined pursuant to this Section 2.1(b)) shall become vested upon the Second Vesting Date, subject, in each case, to the Holders continued employment with the Company or any Subsidiary through the applicable Vesting Date; provided, however, that if Holder incurs a Qualified Termination upon or within two (2) years following a Change in Control and prior to a Vesting Date, the Total Vested Award or Total Target Award, as applicable (and as determined pursuant to this Section 2.1(b)), shall become fully vested upon such Qualified Termination.
Section 2.2 Forfeiture; Effect of Termination.
(a) Termination of Employment. Subject to Section 2.1(b) above and Section 2.2(b) below, in the event of Holders Termination of Employment for any reason prior to a Vesting Date, the then unvested portion of the Award shall automatically be forfeited, terminated and cancelled as of the applicable termination date without payment of any consideration therefor and neither the Company nor Holder shall have any further rights or obligations hereunder with respect to such unvested portion of the Award.
(b) Termination due to Death or Disability.
I. | In the event of Holders Termination of Employment due to Holders death or Disability, in either case, prior to the First Vesting Date, Holder shall be eligible to receive a pro-rated TSR Award (a Pro-Rated TSR Award) equal to the sum of (x) the product of (1) fifty percent (50%) of the amount of the Total Vested Award determined as of the last day of the TSR Performance Period in accordance with Section 2.1(a) and (2) a fraction, the numerator of which is the number of days elapsed from the Closing Date through and including the date of the Holders death or Disability, as applicable, and the denominator of which is the number of days in the period commencing on the Closing Date and ending on the First Vesting Date, and (y) the product of (1) fifty percent (50%) of the amount of the Total Vested Award determined as of the last day of the TSR Performance Period in accordance with Section 2.1(a) and (2) a fraction, the numerator of which is the number of days elapsed from the Closing Date through and including the date of the Holders death or Disability, as applicable, and the denominator of which is the number of days in the period commencing on the Closing Date and ending on the Second Vesting Date. |
II. | In the event of Holders Termination of Employment due to Holders death or Disability, in either case, following the First Vesting Date but prior to the Second Vesting Date, Holder shall be eligible to receive the sum of (a) to the extent the portion of the Award that becomes vested on the First Vesting Date in accordance herewith has not yet been paid to the Holder as of such Holders Termination of Employment, fifty percent (50%) of the Total Vested Award (as calculated in accordance with Section 2.1(a)) and (b) an amount equal to the product of (x) fifty percent (50%) of the Total Vested Award and (y) a fraction, the numerator of which is the number of days elapsed from the Closing Date through and including the date of the Holders death or Disability, as applicable, and the denominator of which is the number of days in the period commencing on the Closing Date and ending on the Second Vesting Date. |
(c) Termination for Cause. In the event of Holders Termination of Employment by the Company for Cause prior to the payment of the Award pursuant to Section 2.3 below, the Award shall automatically be forfeited, terminated and cancelled as of the applicable termination date without payment of any consideration therefor and neither the Company nor Holder shall have any further rights or obligations hereunder.
(d) For purposes of this Section 2.2, Termination of Employment has the definition contained in the Plan; provided, however, that upon the mutual written agreement of the Company and the Holder, Holders cessation of employment shall not be considered a Termination of Employment if Holder continues to hold the position of a member of the Board of Directors of the Company as of the employment termination date, or becomes a member of the Board of Directors as of the employment termination date. Any reference to a Termination of Employment shall thereinafter be the date upon which Holder ceases to be a member of the Board of Directors.
Section 2.3 - Payment. Subject to Section 2.2 above, the portion of the Award that becomes vested (i) on the First Vesting Date in accordance herewith shall be paid to Holder within two and one-half (2.5) months following the First Vesting Date and (ii) on the Second Vesting Date in accordance herewith shall be paid to Holder within two and one-half (2.5) months of the Second Vesting Date; provided, however, that if Holder incurs a Qualified Termination upon or within two
(2) years following a Change in Control and prior to a Vesting Date, the portion of the Award that becomes vested in accordance herewith shall be paid to Holder within thirty (30) days following such Qualified Termination. Notwithstanding the foregoing, in the event of Holders Termination of Employment due to Holders death or Disability, any (x) Pro-Rated TSR Award to which Holder is entitled pursuant to Section 2.2(b)(I) above shall be paid within two and one-half (2.5) months of the First Vesting Date and (y) any Total Vested Award to which Holder is entitled pursuant to Section 2.2(b)(II) above shall be paid within two and one-half (2.5) months of such Holders Termination of Employment, provided that with respect to the portion of the Award that became vested on the First Vesting Date, no later than two and one-half (2.5) months following the First Vesting Date. The Award (or vested portion thereof) shall be paid to Holder in cash or a number of shares of Common Stock with an equivalent Fair Market Value, as determined by the Compensation Committee in its sole discretion. Notwithstanding the foregoing, in the event shares of Common Stock are otherwise payable pursuant to the preceding sentence but cannot be issued pursuant to Section 3.2 (a), (b) (c) or (d) hereof, then the shares of Common Stock shall be issued pursuant to the preceding sentence as soon as administratively practicable after the Compensation Committee determines that shares of Common Stock can again be issued in accordance with Section 3.2 (a), (b), (c) or (d) hereof.
Section 2.4 - Grant is Not Transferable. Except as provided herein, Holder (and Holders legal representative) shall not sell, exchange, transfer, alienate, hypothecate, pledge, encumber or assign the Award other than by will or the laws of descent and distribution, unless and until shares of Common Stock have been issued pursuant to Section 2.3 above. Neither the Award nor any interest or right therein or part thereof shall be liable for the debts, contracts, or engagements of Holder or his successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy) and any attempted disposition thereof shall be null and void and of no effect; provided, however, that, this Section 2.4 shall not prevent transfers subject to the consent of the Compensation Committee, pursuant to a DRO or an analogous non-United States order or procedure.
ARTICLE III
OTHER PROVISIONS
Section 3.1 - Administration. The Compensation Committee shall have the power to interpret the Plan and this Award Agreement, and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith, to interpret, amend or revoke any such rules and to amend this Award Agreement, provided that the rights or obligations of Holder are not affected adversely. All actions taken and all interpretations and determinations made by the Compensation Committee in good faith shall be final and binding upon Holder, the Company and all other interested persons. No member of the Compensation Committee shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan and the Award.
Section 3.2 - Conditions to Issuance of Stock Certificates. Any Common Stock issuable hereunder may be either previously authorized but unissued shares or issued shares which have then been reacquired by the Company and are held as treasury shares available for re-issue. Such shares shall be fully paid and nonassessable. The Company shall not be required to issue or deliver any certificate or certificates (or any account or other evidence representing issuance) for shares of Common Stock or other cash, stock or other property pursuant to this Award Agreement prior to fulfillment of all of the following conditions:
(a) The admission of such shares to listing on all stock exchanges on which such class of stock is then listed, if applicable; and
(b) The completion of any registration or other qualification of such shares under any applicable law or under rulings or regulations of the Securities and Exchange Commission or of any other governmental regulatory body, if applicable, or the receipt of further representations from Holder as to investment intent or completion of other actions necessary to perfect exemptions, as the Compensation Committee shall, in its absolute discretion, deem necessary or advisable; and
(c) The obtaining of any approval or other clearance from any governmental agency which the Compensation Committee shall, in its absolute discretion, determine to be necessary or advisable; and
(d) The lapse of such reasonable period of time as the Compensation Committee may from time to time establish for reasons of administrative convenience; and
(e) The receipt by the Company of payment of any applicable withholding tax in accordance with Section 3.7.
Section 3.3 - Rights as Shareholder. Holder shall not be, nor have any of the rights or privileges of, a shareholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of the Award or any shares of Common Stock issuable thereunder unless and until any such shares shall have been issued by the Company and held of record by Holder pursuant to Section 2.3. No adjustment to the Award will be made for a dividend or other right for which the record date is prior to the date, if any, the shares of Common Stock are issued, except as provided in Section 12.3 of the Plan. Except as otherwise provided herein, upon the delivery of Common Stock, Holder shall have all the rights of a shareholder with respect to the Common Stock, including the right to vote the Common Stock and the right to receive all dividends or other distributions paid or made with respect to the Common Stock.
Section 3.4 - Notices. Any notice to be given under the terms of this Award Agreement to the Company shall be addressed to the Company in care of its Secretary, and any notice to be given to Holder shall be addressed to him at the address given beneath his signature hereto. By a notice given pursuant to this Section 3.4, either party may hereafter designate a different address for notices to be given to him. Any notice which is required to be given to Holder shall, if Holder is then deceased, be given to Holders personal representative if such representative has previously informed the Company of his status and address by written notice under this Section 3.4. Any notice shall be deemed duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.
Section 3.5 - Titles and Construction. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Award Agreement. This Award Agreement shall be administered, interpreted and enforced under the internal laws of the State of New Jersey, without regard to conflicts of laws thereof.
Section 3.6 - Conformity to Securities Laws. Holder acknowledges that the Plan and this Award Agreement are intended to conform to the extent necessary with all provisions of all applicable laws, rules and regulations (including, but not limited to the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, including without limitation the applicable exemptive conditions of Rule 16b-3) and to such approvals by any listing, regulatory or other governmental authority as may, in
the opinion of counsel for the Company, be necessary or advisable in connection therewith. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Award granted, only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by applicable law, the Plan, this Award Agreement and the Award shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.
Section 3.7 - Tax Withholding. The Company (or a Subsidiary) shall be entitled to require payment in cash or deduction from any shares of Common Stock or cash payable under this Award or other compensation payable to Holder of any sums required pursuant to applicable tax law to be withheld with respect to the issuance, vesting or payment of this Award or the shares of Common Stock or cash. Except as otherwise provided by the Compensation Committee in its discretion, in satisfaction of the foregoing requirement, the Company shall withhold shares of Common Stock or cash payable under this Award and Holder hereby elects to transfer and deliver to the Company such cash or shares of Common Stock having a Fair Market Value equal to the sums required to be withheld. Notwithstanding any other provision of the Plan and this Award Agreement, the shares of Common Stock or cash which may be withheld with respect to the issuance, vesting or payment of this Award or the shares of Common Stock in order to satisfy Holders income taxes and payroll tax liabilities and, in the case of Foreign Holders, social insurance, with respect to the issuance, vesting or payment of this Award or the shares of Common Stock or cash shall be limited to the number of shares which have a Fair Market Value, or cash with a value, on the date of withholding equal to the aggregate amount of such liabilities based on the minimum statutory withholding rates for income tax and payroll tax purposes that are applicable to such supplemental taxable income, or such other rate as may be required by applicable law, rule or regulation as determined by the Compensation Committee. If Common Stock is payable under this Award, the Company shall not be obligated to deliver any new certificate representing shares of Common Stock to Holder or Holders legal representative or enter such share of Common Stock in book entry form unless and until Holder or Holders legal representative shall have paid or otherwise satisfied in full the amount of all taxes applicable to the taxable income of Holder resulting from the grant of the Award or the vesting of the Award or issuance of shares of Common Stock.
Section 3.8 Authorization to Release Necessary Personal Information.
(a) In the case of Foreign Holders, Holder hereby authorizes and directs Holders employer or the entity to which Holder provides services to collect, use and transfer in electronic or other form, any personal information (the Data) regarding Holders employment or services, the nature and amount of Holders compensation and the fact and conditions of Holders participation in the Plan (including, but not limited to, Holders name, home address, telephone number, date of birth, social security number (or other applicable social or national identification number), salary, nationality, job title, number of shares of Common Stock held and the details of all Awards or any other entitlement to shares of Common Stock awarded, cancelled, exercised, vested, unvested or outstanding) for the purpose of implementing, administering and managing Holders participation in the Plan. Holder understands that the Data may be transferred to the Company or any of its Subsidiaries, or to any third parties assisting in the implementation, administration and management of the Plan, including any requisite transfer to a broker or other third party assisting with the grant of Awards under the Plan or with whom shares of Common Stock or cash acquired upon settlement of Awards may be deposited. Holder acknowledges that recipients of the Data may be located in different countries, and those countries may have data privacy laws and protections different from those in the country of Holders residence. Furthermore, Holder acknowledges and understands that the transfer of the Data to the Company or any of its Subsidiaries, or to any third parties, is necessary for Holders participation in the Plan.
(b) Holder may at any time withdraw the consents herein, by contacting Holders local human resources representative in writing. Holder further acknowledges that withdrawal of consent may affect Holders ability to realize benefits from the Award, and Holders ability to participate in the Plan.
Section 3.9 - No Entitlement or Claims for Compensation.
(a) Holders rights, if any, in respect of or in connection with Award or any other award is derived solely from the discretionary decision of the Company to permit Holder to participate in the Plan and to benefit from a discretionary award. By accepting this Award, Holder expressly acknowledges that there is no obligation on the part of the Company to continue the Plan and/or grant any additional awards to Holder. This Award is not intended to be compensation of a continuing or recurring nature, or part of Holders normal or expected compensation, and in no way represents any portion of Holders salary, compensation or other remuneration for purposes of pension benefits, severance, redundancy, resignation or any other purpose.
(b) Neither the Plan nor this Award or any other award granted under the Plan shall be deemed to give Holder a right to remain an Employee, Consultant or Director of the Company, a Subsidiary or parent or any other affiliate. The Company and its Subsidiaries, parents and affiliates, as applicable, reserve the right to Terminate the Consultancy, Directorship or Employment of Holder, as applicable, at any time, with or without cause, and for any reason, subject to applicable laws, the Companys Certificate of Incorporation and Bylaws and a written employment or other agreement (if any), and Holder shall be deemed irrevocably to have waived any claim to damages or specific performance for breach of contract or dismissal, compensation for loss of office, tort or otherwise with respect to the Plan, this Award or any outstanding award that is forfeited and/or is terminated by its terms or to any future award.
Section 3.10 - Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to Holders current or future participation in the Plan by electronic means or to request Holders consent to participate in the Plan by electronic means. Holder hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.
Section 3.11 - Foreign Country Appendix. In the case of Foreign Holders, notwithstanding any provisions in this Award Agreement, the Award shall be subject to any special terms and conditions set forth in the Foreign Country Appendix to this Award Agreement for Holders country of residence. Moreover, if Holder relocates to one of the countries included in the Foreign Country Appendix, the special terms and conditions for such country will apply to Holder, to the extent the Company determines that the application of such terms and conditions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan. The Foreign Country Appendix constitutes part of this Award Agreement.
ARTICLE IV
DEFINITIONS
Section 4.1 Definitions. For purposes of this Award Agreement, the following terms shall have their respective meanings set forth below. All capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Plan and/or the Notice of Grant and Signature Page, as applicable. The masculine pronoun shall include the feminine and neuter, and the singular the plural, where the context so indicates.
(a) Beginning Stock Price, with respect to the Company or any other company in the Peer Group, means the average of the closing sales prices for a share of common stock of the applicable company for the forty-five (45) trading days immediately preceding the beginning of the TSR Performance Period, as reported in the Wall Street Journal or such other source as the Compensation Committee deems reliable.
(b) Closing Date means the date on which the closing of the merger between the Company and Allergan, Inc. occured.
(c) Compensation Committee means the Compensation Committee of the Board of Directors of the Company.
(d) Ending Stock Price, with respect to the Company or any other company in the Peer Group, means the average of the closing sales prices for a share of common stock of the applicable company for the forty-five (45) day period ending on, and inclusive of, December 31, 2018, as reported in the Wall Street Journal or such other source as the Compensation Committee deems reliable.
(e) Peer Group means those companies which are included in the NYSE Arca Pharmaceutical Index (the DRG Index) for the entirety of the TSR Performance Period.
(f) Relative TSR Percentile Rank means the percentile rank of the Companys TSR relative to the TSR of the companies in the Peer Group during the TSR Performance Period, determined by the Compensation Committee as set forth on the Adjustments and Defined Terms Appendix to this Award Agreement.
(g) Total Target Award means the Total Target Award set forth in the Notice of Grant and Signature Page.
(h) Total Vested Award means the product of (i) the Total Target Award multiplied by (ii) the TSR Vesting Percentage.
(i) TSR means total shareholder return as applied to the Company and each of the companies in the Peer Group, and will be determined as set forth on the Adjustments and Defined Terms Appendix to this Award Agreement.
(j) TSR Performance Period shall have the meaning set forth in the Adjustments and Defined Terms Appendix to this Award Agreement.
(k) TSR Vesting Percentage shall have the meaning set forth in the Adjustments and Defined Terms Appendix to this Award Agreement.
FOREIGN COUNTRY APPENDIX
TO EXHIBIT 1-A
ADDITIONAL TERMS AND CONDITIONS OF THE AWARD AGREEMENT
Terms and Conditions
This Appendix includes additional terms and conditions that govern Awards granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Foreign Country Appendix (the Appendix) have the meanings set forth in the Plan and/or the Award Agreement.
Notifications
This Appendix also includes information regarding exchange controls and certain other issues of which you should be aware with respect to your participation in the Plans. The information is based on the securities, exchange control and other laws in effect in the respective countries as of June 2010. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the information in this Appendix as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that your Award vests or you sell shares of Common Stock acquired under the Plan.
In addition, the information contained herein is general in nature and may not apply to your particular situation and the Company is not in a position to assure you of a particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.
Finally, if you are a citizen or resident of a country other than the one in which you are currently working, the information contained herein may not be applicable to you.
BRAZIL
Notifications
Exchange Control Information. If you are a resident or domiciled in Brazil, you will be required to submit an annual declaration of assets and rights held outside of Brazil to the Central Bank of Brazil if the aggregate value of such assets and rights is equal to or greater than US$100,000.
CANADA
Notifications
French Language Provision. The following provisions will apply if you are a resident of Quebec:
The parties acknowledge that it is their express wish that this Award Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.
Les parties reconnaissent avoir exigé la redaction en anglais de cette convention (Award Agreement), ainsi que de tous documents exécutés, avis donnés et procedures judiciaries intentées, directement ou indirectement, relativement à la présente convention.
Termination of Service. This provision replaces Section 2.2 of the Award Agreement:
In the event of Termination of Employment, Consultancy or Directorship, as applicable, for any reason (whether or not in breach of local labor laws), the Award (to the extent unvested) shall be immediately forfeited without consideration. For purposes of the preceding sentence, your right to vest in your Award will terminate effective as of the date that is the earlier of (1) the date you receive notice of Termination of Employment, Consultancy or Directorship, as applicable, from the Company or the employer, or (2) the date you are no longer actively employed, regardless of any notice period or period of pay in lieu of such notice required under local law (including, but not limited to statutory law, regulatory law and/or common law); the Company shall have the exclusive discretion to determine when you are no longer actively employed for purposes of your Award.
Authorization to Release and Transfer Necessary Personal Information. This provision supplements the Award Agreement:
You hereby authorize the Company and the Companys representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, or any Subsidiary and the Compensation Committee to disclose and discuss the Plan with their advisors. You further authorize the Company and any Subsidiary to record such information and to keep such information in your employee file.
ICELAND
There are no country specific provisions.
IRELAND
Terms and Conditions
Restriction on Type of Shares Issued to Directors. If you are a director or shadow director of the Company or an Irish Subsidiary or Affiliate of the Company, your Award will be paid in cash or newly issued shares only. Treasury shares will not be used to satisfy the Award.
Notifications
Director Notification Obligation. If you are a director, shadow director or secretary of the Company or an Irish Subsidiary or Affiliate of the Company, you must notify the Company and/or the Irish Subsidiary or Affiliate in writing within five business days of receiving or disposing of an interest in the Company (e.g., the Award, etc.), or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary).
SWITZERLAND
Securities Law Information. The grant of the Award is considered a private offering in Switzerland and is, therefore, not subject to registration in Switzerland.
UNITED KINGDOM
Terms and Conditions
Sub-Plan. All references in the Award Agreement, Notice of Grant and Instructions to the Plan should be replaced with references to the UK specific sub-plan to The 2013 Incentive Award Plan of Actavis plc (the Plan), as appended to the Plan (the Sub-Plan). Only Employees shall be entitled to receive Awards and all references in the Award Agreement to your service shall be replaced with references to your employment.
ADJUSTMENTS AND DEFINED TERMS APPENDIX
TO EXHIBIT 1-A
ADJUSTMENTS; DEFINED TERMS
Adjustments
The Compensation Committee shall equitably adjust or modify the performance goals set forth herein in connection with one or more of the following events: (i) asset write-downs; (ii) significant litigation or claim judgments or settlements; (iii) the effect of changes in tax laws, accounting standards or principles, or other laws or regulatory rules affecting reporting results; (iv) any reorganization and restructuring programs; (v) extraordinary nonrecurring items as described in Accounting Principles Board Opinion No. 30 (or any successor pronouncement thereto) and/or in managements discussion and analysis of financial condition and results of operations appearing in the Companys annual report to shareholders for the applicable year or period; (vi) acquisitions or divestitures; (vii) any other specific, unusual, or nonrecurring events or objectively determinable category thereof; (viii) foreign exchange gains and losses; and (ix) a change in the Companys fiscal year.
Defined Terms
Relative TSR Percentile Rank means the percentile rank of the Companys TSR relative to the TSR of the companies in the Peer Group during the TSR Performance Period, determined by the Compensation Committee as follows: (i) first, the Compensation Committee will rank the TSR of the Company and the companies in the Peer Group (with the company having the lowest TSR being ranked number 1, the company with the second-lowest TSR being ranked number 2, and so on) and (ii) second, the Companys Relative TSR Percentage Rank will be determined by dividing (a) the Companys position in such ranking by (b) the total number of companies in the Peer Group (including, for these purposes, the Company) and rounding to the nearest hundredth.
TSR means total shareholder return as applied to the Company and each of the companies in the Peer Group, and will be equal to (i) (a) the applicable Ending Stock Price minus the applicable Beginning Stock Price, plus (b) dividends paid with respect to a record date occurring during the TSR Performance Period, divided by (ii) the applicable Beginning Stock Price. For purposes of calculating TSR:
(1) Any dividend paid in cash shall be valued at its cash amount. Any dividend paid in securities with a readily ascertainable fair market value shall be valued at the market value of the securities as of the dividend record date.
(2) If any company included in the Peer Group on the Date of Grant (and any successor to such company) does not have a common stock price that is quoted on a national securities exchange at the end of the TSR Performance Period, then such company will be removed from the Peer Group; provided that if any company included in the Peer Group on the Date of Grant (and any successor to such company) (a) files for bankruptcy, reorganization or liquidation under any chapter of the U.S. Bankruptcy Code, (b) is the subject of an involuntary bankruptcy proceeding that is not dismissed within 30 days, (c) is the subject of a shareholder approved plan of liquidation or dissolution or (d) ceases to conduct substantial business operations, the TSR of such company shall be zero (0) for purposes of determining Relative TSR Percentile Rank.
(3) The Compensation Committee may equitably adjust the TSR of any company in the Peer Group in accordance with the Award Agreement.
TSR Performance Period means the period beginning on the Closing Date and ending on December 31, 2018.
TSR Vesting Percentage means a function of the Companys Relative TSR Percentile Rank during the TSR Performance Period and shall be determined as set forth below:
Relative TSR Percentile Rank |
TSR Vesting Percentage | |||
Threshold Level |
50th percentile | 75% | ||
Target Level |
60th percentile | 100% | ||
Maximum Level |
³ 90th percentile | 200% |
In the event that the Relative TSR Percentile Rank is less than the 50th percentile, the TSR Vesting Percentage shall be equal to 0%. In the event that the Relative TSR Percentile Rank during the TSR Performance Period falls between the Threshold Level and the Target Level, the TSR Vesting Percentage shall be determined using straight line linear interpolation between the Threshold Level and the Target Level TSR Vesting Percentages specified above. In the event that the Relative TSR Percentile Rank during the TSR Performance Period falls between the Target Level and the Maximum Level, the TSR Vesting Percentage shall be determined using straight line linear interpolation between the Target Level and the Maximum Level TSR Vesting Percentages specified above. For the avoidance of doubt, notwithstanding the Relative TSR Percentile Rank, in the event the Companys TSR for the TSR Performance Period is a negative number, the TSR Vesting Percentage shall not exceed 100%.
Exhibit 99.1
The following tables represent the segment contribution of Allergan plc for the three months ended June 30, 2016, March 31, 2016, December 31, 2015, September 30, 2015, June 30, 2015 and March 31, 2015:
Three Months Ended June 30, 2016 | ||||||||||||||||
(unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
Eye Care |
$ | 636.1 | $ | | $ | 318.7 | $ | 954.8 | ||||||||
Medical Aesthetics |
419.8 | | 284.1 | 703.9 | ||||||||||||
Gastroenterology |
| 442.0 | | 442.0 | ||||||||||||
Neurosciences & Urology |
326.3 | | | 326.3 | ||||||||||||
CNS |
| 317.5 | | 317.5 | ||||||||||||
Womens Health |
| 296.1 | | 296.1 | ||||||||||||
Medical Dermatology |
97.1 | | | 97.1 | ||||||||||||
Anti - Infectives |
| 63.1 | | 63.1 | ||||||||||||
Other |
9.6 | 330.4 | 154.2 | 494.2 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net revenue |
$ | 1,488.9 | $ | 1,449.1 | $ | 757.0 | $ | 3,695.0 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Cost of sales |
75.1 | 214.9 | 115.0 | 405.0 | ||||||||||||
Selling & marketing |
287.8 | 332.7 | 207.2 | 827.7 | ||||||||||||
General & administrative |
46.0 | 43.7 | 30.9 | 120.6 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Segment contribution |
$ | 1,080.0 | $ | 857.8 | $ | 403.9 | $ | 2,341.7 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Contribution margin |
72.5 | % | 59.2 | % | 53.4 | % | 63.4 | % | ||||||||
Corporate |
308.4 | |||||||||||||||
Research and development |
636.5 | |||||||||||||||
Amortization |
1,633.1 | |||||||||||||||
In-process research and development impairments |
268.9 | |||||||||||||||
Asset sales & impairments, net |
(17.6 | ) | ||||||||||||||
|
|
|||||||||||||||
Operating income/(loss) |
(487.6 | ) | ||||||||||||||
|
|
|||||||||||||||
Operating margin |
-13.2 | % | ||||||||||||||
Three Months Ended March 31, 2016 | ||||||||||||||||
(unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
Eye Care |
$ | 533.0 | $ | | $ | 291.5 | $ | 824.5 | ||||||||
Medical Aesthetics |
373.9 | | 244.9 | 618.8 | ||||||||||||
Gastroenterology |
| 403.6 | | 403.6 | ||||||||||||
Neurosciences & Urology |
306.8 | | | 306.8 | ||||||||||||
CNS |
| 321.6 | | 321.6 | ||||||||||||
Womens Health |
| 263.7 | | 263.7 | ||||||||||||
Medical Dermatology |
69.0 | | | 69.0 | ||||||||||||
Anti - Infectives |
| 51.5 | | 51.5 | ||||||||||||
Other |
16.0 | 413.3 | 136.9 | 566.2 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net revenue |
$ | 1,298.7 | $ | 1,453.7 | $ | 673.3 | $ | 3,425.7 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Cost of sales |
70.7 | 219.6 | 99.2 | 389.5 | ||||||||||||
Selling & marketing |
264.6 | 277.3 | 187.3 | 729.2 | ||||||||||||
General & administrative |
39.2 | 42.2 | 27.6 | 109.0 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Segment contribution |
$ | 924.2 | $ | 914.6 | $ | 359.2 | $ | 2,198.0 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Contribution margin |
71.2 | % | 62.9 | % | 53.3 | % | 64.2 | % | ||||||||
Corporate |
372.4 | |||||||||||||||
Research and development |
403.1 | |||||||||||||||
Amortization |
1,589.7 | |||||||||||||||
In-process research and development impairments |
6.0 | |||||||||||||||
Asset sales & impairments, net |
(1.7 | ) | ||||||||||||||
|
|
|||||||||||||||
Operating income/(loss) |
(171.5 | ) | ||||||||||||||
|
|
|||||||||||||||
Operating margin |
-5.0 | % |
Three Months Ended December 31, 2015 | ||||||||||||||||
(unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
Eye Care |
$ | 618.1 | $ | | $ | 295.0 | $ | 913.1 | ||||||||
Medical Aesthetics |
383.6 | | 246.4 | 630.0 | ||||||||||||
Gastroenterology |
| 436.9 | | 436.9 | ||||||||||||
Neurosciences & Urology |
301.7 | | | 301.7 | ||||||||||||
CNS |
| 356.0 | | 356.0 | ||||||||||||
Womens Health |
| 281.3 | | 281.3 | ||||||||||||
Medical Dermatology |
106.5 | | | 106.5 | ||||||||||||
Anti - Infectives |
| 50.5 | | 50.5 | ||||||||||||
Other |
10.3 | 410.0 | 149.5 | 569.8 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net revenue |
$ | 1,420.2 | $ | 1,534.7 | $ | 690.9 | $ | 3,645.8 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Cost of sales |
75.6 | 235.5 | 107.1 | 418.2 | ||||||||||||
Selling & marketing |
247.8 | 277.6 | 175.0 | 700.4 | ||||||||||||
General & administrative |
22.2 | 16.5 | 31.9 | 70.6 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Segment contribution |
$ | 1,074.6 | $ | 1,005.1 | $ | 376.9 | $ | 2,456.6 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Contribution margin |
75.7 | % | 65.5 | % | 54.6 | % | 67.4 | % | ||||||||
Corporate |
727.8 | |||||||||||||||
Research and development |
430.6 | |||||||||||||||
Amortization |
1,584.9 | |||||||||||||||
In-process research and development impairments |
14.0 | |||||||||||||||
Asset sales & impairments, net |
268.9 | |||||||||||||||
|
|
|||||||||||||||
Operating income/(loss) |
(569.6 | ) | ||||||||||||||
|
|
|||||||||||||||
Operating margin |
-15.6 | % | ||||||||||||||
Three Months Ended September 30, 2015 | ||||||||||||||||
(unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
Eye Care |
$ | 539.9 | $ | | $ | 281.5 | $ | 821.4 | ||||||||
Medical Aesthetics |
340.1 | | 214.8 | 554.9 | ||||||||||||
Gastroenterology |
| 398.6 | | 398.6 | ||||||||||||
Neurosciences & Urology |
291.4 | | | 291.4 | ||||||||||||
CNS |
| 406.7 | | 406.7 | ||||||||||||
Womens Health |
| 268.0 | | 268.0 | ||||||||||||
Medical Dermatology |
107.8 | | | 107.8 | ||||||||||||
Anti - Infectives |
| 52.3 | | 52.3 | ||||||||||||
Other |
17.4 | 426.4 | 164.3 | 608.1 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net revenue |
$ | 1,296.6 | $ | 1,552.0 | $ | 660.6 | $ | 3,509.2 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Cost of sales |
71.6 | 227.5 | 108.3 | 407.4 | ||||||||||||
Selling & marketing |
236.2 | 262.8 | 155.8 | 654.8 | ||||||||||||
General & administrative |
17.2 | 17.5 | 33.3 | 68.0 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Segment contribution |
$ | 971.6 | $ | 1,044.2 | $ | 363.2 | $ | 2,379.0 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Contribution margin |
74.9 | % | 67.3 | % | 55.0 | % | 67.8 | % | ||||||||
Corporate |
642.6 | |||||||||||||||
Research and development |
1,260.5 | |||||||||||||||
Amortization |
1,557.8 | |||||||||||||||
In-process research and development impairments |
300.0 | |||||||||||||||
Asset sales & impairments, net |
(4.4 | ) | ||||||||||||||
|
|
|||||||||||||||
Operating income/(loss) |
(1,377.5 | ) | ||||||||||||||
|
|
|||||||||||||||
Operating margin |
-39.3 | % |
Three Months Ended June 30, 2015 | ||||||||||||||||
(unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
Eye Care |
$ | 578.6 | $ | | $ | 301.7 | $ | 880.3 | ||||||||
Medical Aesthetics |
366.2 | | 262.2 | 628.4 | ||||||||||||
Gastroenterology |
| 373.2 | | 373.2 | ||||||||||||
Neurosciences & Urology |
277.7 | | | 277.7 | ||||||||||||
CNS |
| 560.8 | | 560.8 | ||||||||||||
Womens Health |
| 219.4 | | 219.4 | ||||||||||||
Medical Dermatology |
120.7 | | | 120.7 | ||||||||||||
Anti - Infectives |
| 44.1 | | 44.1 | ||||||||||||
Other |
4.5 | 410.5 | 153.2 | 568.2 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net revenue |
$ | 1,347.7 | $ | 1,608.0 | $ | 717.1 | $ | 3,672.8 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Cost of sales |
74.4 | 238.0 | 111.8 | 424.2 | ||||||||||||
Selling & marketing |
247.8 | 309.2 | 196.1 | 753.1 | ||||||||||||
General & administrative |
20.9 | 18.1 | 35.0 | 74.0 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Segment contribution |
$ | 1,004.6 | $ | 1,042.7 | $ | 374.2 | $ | 2,421.5 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Contribution margin |
74.5 | % | 64.8 | % | 52.2 | % | 65.9 | % | ||||||||
Corporate |
831.7 | |||||||||||||||
Research and development |
349.7 | |||||||||||||||
Amortization |
1,515.7 | |||||||||||||||
In-process research and development impairments |
197.6 | |||||||||||||||
Asset sales & impairments, net |
2.9 | |||||||||||||||
|
|
|||||||||||||||
Operating income/(loss) |
(476.1 | ) | ||||||||||||||
|
|
|||||||||||||||
Operating margin |
-13.0 | % | ||||||||||||||
Three Months Ended March 31, 2015 | ||||||||||||||||
(unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
Eye Care |
$ | 94.7 | $ | | $ | 40.5 | $ | 135.2 | ||||||||
Medical Aesthetics |
55.1 | | 32.9 | 88.0 | ||||||||||||
Gastroenterology |
| 366.6 | | 366.6 | ||||||||||||
Neurosciences & Urology |
68.1 | | | 68.1 | ||||||||||||
CNS |
| 517.6 | | 517.6 | ||||||||||||
Womens Health |
| 229.3 | | 229.3 | ||||||||||||
Medical Dermatology |
20.9 | | | 20.9 | ||||||||||||
Anti - Infectives |
| 41.9 | | 41.9 | ||||||||||||
Other |
6.5 | 488.3 | 45.3 | 540.1 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net revenue |
$ | 245.3 | $ | 1,643.7 | $ | 118.7 | $ | 2,007.7 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Cost of sales |
14.2 | 208.5 | 23.7 | 246.4 | ||||||||||||
Selling & marketing |
41.0 | 345.1 | 42.3 | 428.4 | ||||||||||||
General & administrative |
8.0 | 53.2 | 7.4 | 68.6 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Segment contribution |
$ | 182.1 | $ | 1,036.9 | $ | 45.3 | $ | 1,264.3 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Contribution margin |
74.2 | % | 63.1 | % | 38.2 | % | 63.0 | % | ||||||||
Corporate |
864.6 | |||||||||||||||
Research and development |
317.7 | |||||||||||||||
Amortization |
785.4 | |||||||||||||||
In-process research and development impairments |
| |||||||||||||||
Asset sales & impairments, net |
4.6 | |||||||||||||||
|
|
|||||||||||||||
Operating income/(loss) |
(708.0 | ) | ||||||||||||||
|
|
|||||||||||||||
Operating margin |
-35.3 | % |